Replies to post #218567 on Biotech Values

[kris_kade]

Agree. I listened to the interview as well. Sharp guy and he is careful not pumping the pipeline until P3 is out but at the same time he is confident on P2 data for efficacy & safety superiority.

APD371 probable success not built into valuation.